Deramiocel
Capricor Therapeutics (CAPR)
Decision dateNov 22, 2026
7 days away
Marketer take
The FDA advisory committee voted against effectiveness in July 2026 and the date was extended, so DMD teams should treat the outcome as uncertain.
- Sponsor company
- Capricor Therapeutics (CAPR)
- Indication
- Duchenne muscular dystrophy (DMD) cardiomyopathy
- Therapeutic area
- Neurology, Rare disease
- Event
- PDUFA target action date
- Date
- Nov 22, 2026
- Status
- Delayed
- Source
- SEC filing
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?